Despite multiple improvements in management, including molecular markers, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) targeted treatments as well as immune checkpoint inhibitors, that have resulted in improvement in lung cancer mortality, there remains a significant risk of metastases [3]. The gene discussed is ALK; the disease is lung cancer.